Hot word :

Home>Science & Nature>Science

Science

iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

scanner main-2

Return to article

By Masahiro Amazawa, Shiyori Iwase and Yusuke Tomiyama / Yomiuri Shimbun Staff Writers

18:15 JST, February 20, 2026

A health ministry panel has conditionally approved, for a limited time, two regenerative medical products derived from induced pluripotent stem (iPS) cells, a key milestone in the possible wider use and commercialization of iPS cell treatments.

Add TheJapanNews to your Google News feed.

New contents

JN ACCESS RANKING